RetinaCME

This activity is expired and is no longer available for CME credit.

EXPERT INTERVIEWCME

What Adverse Events Are Associated with the Use Bevacizumab in Treating ROP?

Author(s)/Faculty: Maria Martinez-Castellanos, MD
Release Date: 5/18/2012Expiration Date: 5/17/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
After 5 years of follow up, IB appears to be safe for ROP, with treatable ocular adverse events. Systemic abnormalities may be sequelae of prematurity itself and not related to the medication. Longer follow-up is needed...